Hatem Soliman, MD

Hatem Soliman, MD, highlights the crucial role of HER2 targeting and staying informed about evolving treatment options for better patient outcomes in the HER2-positive breast cancer space.

Hatem Soliman, MD, discusses what unmet needs still have to be addressed in the HER2-positive breast cancer space.

Hatem Soliman, MD, discusses future directions for the HER2-positive breast cancer treatment landscape.

Hatem Soliman, MD, discusses some of the exciting research that is ongoing for patients with HER2-positive breast cancer.

Hatem Soliman, MD, discusses second- and third-line strategies being used for the treatment of patients with HER2-positive metastatic breast cancer.

Hatem Soliman, MD, discusses fam-trastuzumab deruxtecan-nxki and its importance for patients with HER2-positive breast cancer.

Hatem Soliman, MD, discusses the current first-line treatment options for patients with HER2-positive breast cancer.

Hatem Soliman, MD, explains how to test for HER2 status in patients with breast cancer.